22-555 Phase II
A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants with Aggressive and Indolent B-cell Malignancies
Search Cancer Clinical Trials
Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
22 results
21-481 Phase I
A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination with Toripalimab in Subjects with Advanced Solid Malignancies including Lymphoma
21-258 Phase II
A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab
20-404 Phase II
A multicenter phase 2 study of belantamab mafodotin in relapsed or refractory plasmablastic lymphoma and ALK+ large B-cell lymphoma
20-508 Phase I
A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies
21-245 Phase II
A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma or Multiple Myeloma
23-177 Phase II
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter’s Syndrome
22-149 Phase II
A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
21-422 Phase II
A Phase 2 Study of acalabrutinib in combination with lisocabtagene maraleucel in relapsed/refractory aggressive B-cell lymphomas
19-743 Phase II
A Phase 2 Study of MRD Adapted Therapy with Venetoclax-Obinutuzumab in Patients with High or Intermediate Risk Relapsed or Refractory CLL, with Addition of Acalabrutinib in Patients who Fail to Achieve MRD Eradication
Showing 1 - 10 of 22 results